Injectable Cababatine®

Solution for injection.

Initial emergency treatment for anticoagulant rodenticide poisoning.

Dogs.

Each 1 mL of solution for injection contains:
Phytomenadione……………………………….10 mg
Excipients c.s.p……………………………….1 mL

Vitamin K is a cofactor in the last stage of hepatic synthesis of coagulation factors II (prothrombin), VII (proconvertin), IX (thromboplastin component of plasma), and X (Stuart’s factor).
In veterinary medicine, the most frequent cause of cessation of formation of K-dependent coagulation factors is poisoning by anticoagulant rodenticides.
Phytomenadione (Vitamin K1) antagonizes the effects of anticoagulant rodenticidal agents and allows the production process of K-dependent coagulation factors to be reactivated.

Injectable Cabatine® is indicated for the initial emergency treatment of acute and superacute poisonings generated by anticoagulant rodenticides.

• Initial Emergency Treatment:
  Administer 2.5 to 5 mL of Injectable Cababatina® product for every 10 kg of body weight (equivalent to 2.5 – 5 mg/kg of body weight of Phytomenadione, respectively), in a single dose. According to the evolution of the clinical picture, the type of rodenticide responsible for the poisoning and the criteria of the treating veterinarian, continue treatment with another veterinary drug based on Phytomenadione for oral administration.
• Cases that require continuing with injectable treatment:
  In those cases where after the emergency dose, it is not possible to establish an oral administration therapy, treatment with the product Injectable Cababatina® may be continued, in doses of 2.5 mL of product per 10 kg of body weight (equivalent to 2.5 mg/kg of body weight of Phytomenadione), every 12 hours. with a maximum of 4 administrations in total.
  The duration of injectable treatment (between 1 and 4 administrations) will depend on the type of rodenticide responsible for the poisoning, the evolution of the clinical picture and the criteria of the treating veterinarian. Treatment with another veterinary medicinal product based on Phytomenadione for oral administration may then be continued.

Subcutaneous.

Administer the dose of the product at several injection sites to accelerate its absorption and using needles of the smallest caliber possible, to minimize the risk of bleeding.

• Therapy with injectable cabatine® administered subcutaneously should be continued by oral administration of Phytomenadione (Vitamin K1).
• In animals with vomiting, anorexia or acute/overacute conditions, in which Phytomenadione (Vitamin K1) cannot be administered orally, administration by subcutaneous route is recommended, however, subcutaneous administration should be replaced by the oral route, as soon as possible.
• Subcutaneous injections may be poorly absorbed in hypovolemic animals.
• Phytomenadione (Vitamin K1) does not correct hypoprothrombinemia resulting from hepatocellular damage.
• In case of emergency due to lack of clotting factors, blood transfusions or blood products should be administered, as it takes approximately 6 to 12 hours from the administration of Phytomenadione (Vitamin K1) for new clotting factors to be formed.
• Keep out of reach of children and pets.

The following medications may prolong or enhance the effects of anticoagulants and antagonize some of the therapeutic actions of Phytomenadione (Vitamin K1): Phenylbutazone, Acetylsalicylic Acid, Chloramphenicol, Sulfonamides (including Sulfa/Trimethoprim), Diazoxide, Allopurinol, Cimetidine, Metronidazole, Anabolic steroids, Erythromycin, Ketoconazole, Propanolol and thyroid drugs, therefore it is not recommended to use concomitantly with other products pharmacists.

• Do not administer in animals with known hypersensitivity to Phytomenadione (Vitamin K1).
• Do not administer in patients with severe hepatic impairment.
• Do not administer intravenously due to the risk of anaphylactic reactions.
• Do not administer intramuscularly due to the risk of bleeding and bruising.
• Do not administer the product for more than 4 administrations due to the risk of hemolysis.

Exogenous Phytomenadione (Vitamin K1) enters milk and crosses the placental barrier. There are no formal investigations on the safety of Phytomenadione during pregnancy, therefore, it should be used only according to the benefit/risk assessment carried out by the treating Veterinarian.

• High doses of Phytomenadione (Vitamin K1) should be administered with caution because Heinz body anemia has been reported in dogs that received doses of 4 mg/kg for 5 days.
• In some dogs, cases of urticaria and abscess formation have been reported after subcutaneous administration of Phytomenadione (Vitamin K1).

• In the case of eye exposure, the eyes should be irrigated with plenty of water at room temperature for at least 15 minutes. If irritation, pain, inflammation, tearing, or photophobia persist, the patient should be evaluated by a physician.
• In the case of dermal exposure, contaminated clothing should be removed and the exposed area thoroughly washed with soap and water. If irritation or pain is present, the patient should be evaluated by a physician.
• In the case of accidental injection, medical attention should be sought.

Keep the product, closed or once opened, at a temperature between 2 and 30 ºC, away from light.
Once opened, use the product within 2 weeks. Discard the unused product after that period of time.

Dispose of unused product residues in their original, tightly closed containers. Dispose of waste of this product with caution along with household waste.

Sale by prescription to the Veterinary Doctor.

VETERINARY USE

Chile: Reg. SAG N° 2329
Bolivia: Reg. SENASAG PUV-No 009995/21

Ampoule bottle with 20 mL.

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.